Posted by Michael Wonder on 03 Sep 2020
Tolak is included in the high-cost protection
2 September 2020 - Tolak, a topical treatment for adults with non-hyperkeratotic and non-hypertrophic actinic keratosis (Olsen grade I and II) on the face, ears, and/or scalp, is included in the high-cost protection from 28 August 2020.
TLV determined that the relevant comparison alternative to Tolak consists of two imiquimod based creams, Aldara and Zyclara.
According to TLV's assessment, the effect is comparable between Tolak, Aldara and Zyclara and that the costs of treatment with Tolak are lower than the costs of treatment with either Aldara or Zyclara.
